Clinical trial NCT00708942: Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1
Official title: A Randomized Phase II Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) in Patients With Low-grade Cervical Intraepithelial Neoplasia (CIN1)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Cervical Intraepithelial Neoplasia
Keywords: Cervical intraepithelial neoplasia (CIN)
Lead sponsor: Photocure
Sponsor class: INDUSTRY
First posted: 2008-07-03
Enrollment: 83
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study will examine the effect of HAL vs placebo photodynamic therapy of low-grade cervical precancerous lesions (dysplasia) in women.

Detailed description: Low-grade cervical intraepithelial neoplasia (CIN1) is caused by persistent HPV infection and may worse case develop into cancer. In most cases both the virus infection and lesions (CIN1) regress spontaneously, but must be followed up with gynecological examinations to ensure normalization. If further persistent disease and worsening to precancerous lesions (CIN2-3), the usual treatment is surgery, where one removes the tissue in the cervix where the CIN lesions are.

In this research study we will evaluate a new non-surgical treatment for CIN1 using hexaminolevulinate (HAL) photodynamic therapy (PDT). HAL PDT is the combination of a medication and a specific type of light to activate the drug. HAL PDT selectively removes CIN lesions while preserving normal tissue, thus this may be an alternative to frequent gynecological consultations and local surgery that may have undesirable side effects.

Eligibility criteria: Inclusion Criteria:

* Satisfactory colposcopy examination
* Negative endocervical canal by colposcopy
* Ectocervical CIN1 as verified by local pathologist (biopsy).
* Colposcopical visible lesion at visit 2, before photoactivation
* Written Informed Consent signed
* Age 18 or above

Exclusion Criteria:

* Previous treatment of CIN or invasive disease or suspicion of either micro-invasive or invasive disease
* Malignant cells on cytology or histology
* Atypical glandular cells (AGC) or adenocarcinoma in situ (AIS) on cytology
* Suspicion of endocervical disease on colposcopy
* Current pelvic inflammatory disease, cervicitis, or other gynecological infection as per colposcopy and clinical examination
* Known or suspected porphyria
* Known allergy to hexaminolevulinate or similar compounds (e.g. methyl aminolevulinate or aminolevulinic acid)
* Use of heart pacemaker
* Pregnancy
* Nursing
* Childbirth or miscarriage within six weeks of enrolment - Known
* Participation in other "competitive" clinical studies either concurrently or within the last 30 days
* Risk of poor protocol compliance
* Not willing to use adequate birth control from screening until last PDT
* Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.

Primary outcomes:
measure: Complete Response Rate
timeFrame: 6 month
Secondary outcomes:
measure: Eradication of HPV
timeFrame: 6 months
measure: Incidence of Patients With Adverse Events
timeFrame: 3 months
Other outcomes:
Locations:
city: Lille
country: France
facility: Department of Obstetrics and Gyneacology, Lille University Hospital
city: Hannover
country: Germany
facility: Department of Obstetrics and Gynecology
city: Larvik
country: Norway
facility: Fritzøe klinikk
city: Oslo
country: Norway
facility: Department of Obstetrics and Gynaecology, Ullevål University Hospital
city: Trondheim
country: Norway
facility: Medicus
Study officials:
affiliation: Medizinische Hochschule Hannover, Hannover, Germany
name: Peter Hillemanns, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: